Pediatrix Medical Group, Inc 8-K, filed Dec 5, 2024
Pediatrix Medical Group, Inc. (MD)
About this 8-K
Pediatrix Medical Group, Inc filed this 8-K on December 5, 2024, reporting on events of November 29, 2024.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 5, 2024, Pediatrix Medical Group, Inc., a Florida corporation (the “Company”), and Dr. Curtis B. Pickert, the current Executive Vice President, Chief Physician Executive and former Chief Operating Officer of the Company, announced that Dr. Pickert would transition from his role at the Company, effective as of January 31, 2025. Dr. Pickert was notified by the Company of his transition on November 29, 2024.
Dr. Pickert’s transition from his role as Executive Vice President and Chief Physician Executive is a termination without “Cause” pursuant to that certain Second Amended and Restated Employment Agreement, dated April 26, 2023, by and between Dr. Pickert and a wholly-owned subsidiary of the Company, and Dr. Pickert will receive the benefits thereunder following the execution of a general release of claims in favor of the Company.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
Pediatrix Medical Group, Inc. |
|
|
|
|
Date: |
December 5, 2024 |
By: |
/s/ Kasandra H. Rossi |
|
|
|
Kasandra H. Rossi |